Blog
RSS FeedPosted by Michael Wonder on 10 Oct 2019
Swissmedic reviewing licence extension for the SGLT2 inhibitor Invokana (canagliflozin) in fast-track procedure
9 October 2019 - The CREDENCE renal outcomes study, which was stopped early in July 2018 owing to positive efficacy findings, ...
Posted by Michael Wonder on 17 Oct 2017
Swissmedic updates requirements concerning the fast-track authorisation procedure
16 October 2017 - On 1 October 2017, the Swiss Agency for therapeutic products updated its guidance document concerning the ...